WCRC-25 is a novel metastatic lobular carcinoma cell line derived from a pleural effusion of a postmenopausal Caucasian patient. This model is characterized by ER-negative status while displaying both luminal and Her2-like traits. It carries a CDH1 Q706* truncating mutation as well as critical mutations in FOXA1, CTCF, BRCA2, and TP53, offering a well-characterized genomic framework. Established in a controlled laboratory environment with rigorous consent protocols, it has been meticulously developed to serve as an effective in vitro platform for studying breast cancer biology and therapeutic responses.
Description
What distinguishes WCRC-25 is its comprehensive molecular profile, which addresses the pressing need for robust models in invasive lobular carcinoma research. Its dual luminal and Her2-like features, combined with the presence of clinically significant gene mutations, provide an unprecedented opportunity for detailed exploration of tumor biology. This tool has gained recognition in prominent scientific forums and is being shared with the broader research community through established agreements, enhancing collaborative efforts to advance treatment strategies for breast cancer.
Applications
- Preclinical drug screening
- Diagnostic assay development
- Biomarker discovery research
- Therapeutic resistance testing
- Precision oncology studies
Advantages
- Provides a novel and well-characterized in vitro model for studying invasive lobular carcinoma.
- Features a unique molecular profile with clinically relevant mutations, such as CDH1, FOXA1, CTCF, BRCA2, and TP53.
- Addresses a critical gap in available breast cancer research models, particularly for ER-negative ILC.
- Facilitates advanced research into cancer biology and treatment strategies, including therapeutic responses.
IP Status
Research Tool
